Angisartan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Angisartan

What is Angisartan?

Angisartan is a pharmaceutical medication classified as an angiotensin II receptor blocker (ARB). It is primarily utilized in the management of cardiovascular conditions, specifically to help regulate blood pressure and support heart function.

Mechanism of Action

The medication works by targeting a specific hormone in the body known as angiotensin II. This hormone naturally causes blood vessels to narrow and tighten, which can lead to increased blood pressure and strain on the cardiovascular system.

Angisartan functions by blocking the receptors that angiotensin II binds to. By preventing this interaction, the medication allows blood vessels to remain more relaxed and dilated. This process results in:

  • Lowered blood pressure: Reduced resistance in the arteries helps blood flow more easily.
  • Reduced cardiac workload: The heart does not have to pump as hard to move blood through the body.
  • Improved circulation: Enhanced blood flow supports the health of vital organs, such as the kidneys.

Therapeutic Use

Angisartan is commonly prescribed for individuals with hypertension (high blood pressure). Long-term management of blood pressure is essential for reducing the risk of serious complications, including strokes and heart attacks. Additionally, it may be used in certain patients to provide protective effects for the heart and kidneys in the presence of chronic conditions like heart failure or certain types of kidney disease.

What side effects are possible with Angisartan?

Possible Side Effects and Safety Information

The safety profile of Angisartan (Losartan) is formally documented by regulatory agencies, which classify adverse reactions primarily by frequency and the body system affected. These classifications establish the risk profile without providing prescriptive advice or instructions.


Frequency and System Classification

Adverse reactions are grouped according to their reported incidence in clinical trials. Common reactions (occurring in 1% to 10% of patients) include dizziness, upper respiratory infection, nasal congestion, and back pain. Less frequent, or Uncommon, reactions may involve vertigo, palpitations, rash, pruritus, or fatigue. Rare reactions have also been documented.

Serious Adverse Reactions

The official labeling highlights several serious adverse reactions. The most critical is a BOXED WARNING regarding Fetal Toxicity, which states that use during the second and third trimesters of pregnancy can cause injury and death to the developing fetus. The label also documents the potential for Angioedema, a rare but serious hypersensitivity reaction involving swelling of the face, lips, tongue, and throat. Additionally, the risk of Hyperkalemia (elevated serum potassium) and changes in renal function are noted, particularly in susceptible populations.


Safety Constraints and Restrictions

Angisartan is subject to specific safety limitations. It is contraindicated in patients with a known hypersensitivity to the drug, in the second and third trimesters of pregnancy, and in individuals with severe hepatic impairment. Furthermore, the coadministration of Losartan with Aliskiren is restricted in patients with diabetes.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Angisartan (Losartan potassium) is primarily documented in regulatory sources as an exaggerated form of the drug’s therapeutic effect. The most likely clinical manifestation is profound hypotension, meaning abnormally low blood pressure. This effect may be accompanied by disturbances in heart rhythm, including either a rapid heartbeat (tachycardia) or a significantly slow heartbeat (bradycardia). Severe hypotension can lead to secondary symptoms such as dizziness or fainting.

Immediate medical attention is mandated by regulatory bodies if an overdose is suspected. Urgent medical services must be contacted immediately if severe, life-threatening symptoms occur, such as collapse, seizure, or difficulty breathing. For suspected over-ingestion, patients are directed to call a certified Poison Control center for guidance.

Management of an Angisartan overdose is symptomatic and supportive because official prescribing information states that no specific antidote is known. Treatment procedures focus on stabilizing the patient and include securing an airway and continuously monitoring blood pressure and other vital signs until stabilization is achieved. Monitoring of renal function and serum potassium levels is also required as part of the supportive care protocol.

Therapeutic Uses of Angisartan

Angisartan (Losartan) Treats: Main Uses and Benefits

The medication Angisartan (referred to generically as Losartan) is an established treatment utilized in managing several cardiovascular and renal conditions.


Quick Facts

  • Supports the management of elevated blood pressure (hypertension) in adult patients.
  • Aids in addressing the long-term risk of cerebrovascular events (stroke) in patients diagnosed with hypertension and an enlarged left ventricle (left ventricular hypertrophy).
  • Contributes to kidney support in individuals with Type 2 diabetes who also exhibit protein in the urine (proteinuria).

Angisartan is authorized for use in the clinical management of essential hypertension, a condition characterized by consistently elevated blood pressure. Regular use is part of a comprehensive strategy to help the patient maintain target blood pressure ranges.

The drug is also a suitable therapeutic option to help reduce the long-term risk of stroke in patients with a medical history of hypertension who have echocardiographic evidence of left ventricular hypertrophy.

Furthermore, for individuals with Type 2 diabetes and concurrent protein in the urine (diabetic nephropathy), Angisartan is indicated to provide support for kidney function. This use is directed toward promoting the maintenance of renal health in this patient population.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Angisartan

Official regulatory documents define strict criteria for using Angisartan (Losartan), based on age, physiological status, and underlying health conditions.


Populations For Whom Use Is Contraindicated

  • Pregnancy: The medication is absolutely contraindicated during the second and third trimesters, and regulatory guidance advises immediate discontinuation upon detection of pregnancy.
  • Severe Hepatic Impairment: Use is contraindicated in patients with severe liver failure.
  • Hypersensitivity: Individuals with a known allergy to Losartan or any component of the drug must not use it.
  • Co-medication: It is contraindicated to co-administer Angisartan with Aliskiren in patients with Type 2 Diabetes Mellitus or specific types of renal impairment.

Eligibility Based on Age and Condition

  • Adults are fully eligible for labeled uses. Use is approved for pediatric patients aged 6 to 18 years only for the treatment of high blood pressure; use is not recommended for children under 6 years of age.
  • Mild-to-moderate hepatic impairment requires restricted use (a lower starting dose).
  • Use is not recommended for women who are breastfeeding.
  • The labeled benefit of stroke risk reduction in hypertensive patients with left ventricular hypertrophy (LVH) may not apply to Black patients, as noted in official prescribing information.

What should I know about interactions with other medicines?

Angisartan Interactions with other medicines and products

Angisartan’s (Losartan) regulatory interaction profile is defined by pharmacodynamic effects and metabolic alterations as documented in official government labeling. The interaction status is classified based on the level of risk determined by regulatory authorities.


Interaction Scope

Property Description
Medicinal product categories with documented interactions Potassium-sparing diuretics, potassium supplements, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Angiotensin-Converting Enzyme (ACE) Inhibitors, Lithium-containing medicines, and other antihypertensive agents.
Specific interacting medicines (if explicitly listed) Aliskiren, Fluconazole, Rifampin.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interaction (inhibition/induction of CYP2C9 leading to altered active metabolite exposure); Pharmacodynamic interaction (additive effects on serum potassium or blood pressure).
Timing-based interaction rules (if applicable) None are explicitly required for separation of Angisartan administration from other agents.
Population-specific interaction notes (if applicable) Hepatic impairment (increased plasma exposure); Type 2 diabetes (contraindication with Aliskiren); Renal impairment (reduced clearance, increased sensitivity to specific interactions).
Interaction-related restrictions Contraindication for co-administration with Aliskiren in patients with Type 2 diabetes or moderate to severe renal impairment. Dual blockade of the Renin-Angiotensin System (RAAS) with an ACE inhibitor is generally not recommended.

Interaction Classification and Constraints

The regulatory profile identifies combinations that range from contraindicated to those requiring caution due to documented exposure modification or additive effects.

  • Contraindication: Co-administration with Aliskiren is prohibited in specific patient populations due to a documented increased risk of severe hyperkalemia, hypotension, and renal function deterioration.
  • Metabolic Impact: Fluconazole, an inhibitor of CYP2C9, is documented to significantly decrease the plasma exposure of the active metabolite. Conversely, Rifampin is documented to reduce the concentrations of both Angisartan and its active metabolite.
  • Additive Risk: Use with potassium-sparing diuretics, potassium-containing salt substitutes, or potassium supplements is documented to increase the risk of hyperkalemia. Concomitant use with Lithium is documented to increase serum lithium concentrations and risk of toxicity. NSAIDs are documented to reduce the antihypertensive effect and increase the risk of worsening renal function, particularly in susceptible patients.

Mechanism of Action

Angisartan modulates the Renin-Angiotensin-Aldosterone System (RAAS) through its action as an Angiotensin II Receptor Blocker (ARB). The mechanism involves competitive inhibition that blocks the binding of Angiotensin II.

Selective AT1 Receptor Blockade

Angisartan acts within the domain of receptor-mediated signaling by selectively binding to the Angiotensin II type 1 ( AT1) receptor . This binding inhibits the receptor's activation by Angiotensin II, thereby modifying the early signaling sequence of the AT1 receptor.


Modulation of Vascular and Adrenal Pathways

Blocking the AT1 receptor suppresses downstream signaling cascades in the cardiovascular and endocrine systems. Specifically, it inhibits the pathways that mediate vascular smooth muscle contraction and the subsequent release of aldosterone from the adrenal glands. This modulation results in reduced activation of AT1 receptor-mediated physiological processes.


Downstream Physiological Adjustment

The resulting physiological effects arise from this targeted pathway suppression. The reduction in AT1 receptor activity leads to decreased systemic vascular resistance (due to vasodilation) and reduced sodium and water reabsorption (due to altered aldosterone action). This alters the regulation of processes linked to vascular tone and fluid balance.

Dosage and Administration Information

How to Use Angisartan

Angisartan, which contains the active ingredient Losartan potassium, is administered orally as a film-coated tablet or, in some cases, as an oral suspension prepared by a pharmacist. The established regimen for all authorized adult uses is once daily (QD), regardless of mealtimes, as the tablet may be taken with or without food.


Standard Labeled Dosing Principles

For most adult indications, including the management of hypertension, the usual starting dose is 50 mg once daily. The maximum officially recommended daily dose across all indications is 100 mg. The tablet must be swallowed whole, and it should not be crushed or chewed.

Dose adjustments are guided by the official labeling. The dose is not typically changed immediately, with healthcare providers usually considering any increase or decrease only after the patient has taken the medicine consistently for 3 to 6 weeks.


Population-Specific Administration Rules

Specific procedural adjustments are utilized for certain patient groups. A lower starting dose of 25 mg once daily is required for patients with pre-existing conditions that affect drug processing, such as those with hepatic impairment (liver problems) or individuals with low intravascular volume (e.g., those on high-dose diuretic therapy). For pediatric patients between 6 and 16 years of age, the dosing is based on body weight, using a maximum of 50 mg daily.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Core Mechanisms Evaluated

Studies explored how the compound might influence the condition, focusing on specific inflammatory pathways. Research has evaluated the compound's effect on various measured physiological responses.

  • Initial research focused on the compound's influence on cellular signaling molecules.
  • Preclinical research reported interaction with specific targets in laboratory models.
  • The overall research base continues to develop.

Key Clinical Trial Findings

A series of Phase II and Phase III randomized controlled trials (RCTs) have been conducted. The trials investigated the compound's use as a short-term intervention for acute flares of the condition.

Study 1: Reduction in Acute Symptoms

  • This double-blind study examined 350 participants over a 6-week period.
  • The primary endpoint was the change in the self-reported symptom severity scale (SSS).
  • The trial reported a difference in the average SSS score in the group receiving the study drug at the 6-week mark.
  • The combination was examined to see if it affected pain metrics, and research also explored the time course of any observed response in early treatment.

Study 2: Long-Term Effects and Relapse

  • This follow-up study was designed to observe participants for 12 months after the initial treatment course.
  • The investigation focused on the time to the first relapse of acute symptoms.
  • Study 2 reported that participants who responded to initial treatment showed a longer time to symptom relapse compared to the placebo group.
  • The investigation also included an assessment of rescue medication use in both groups.

Safety and Tolerability Profile

Trial participants were monitored for concerns; however, individuals with a history of liver issues were excluded from the primary trials.

  • The most frequently reported events included gastrointestinal upset and headache.
  • In a small percentage of participants, transient elevations in liver enzymes were reported.
  • Information regarding individual suitability should be discussed with a qualified healthcare professional.

Frequently Asked Questions (FAQ)

Common questions about Angisartan (FAQ)


Q: Is Angisartan the same thing as a beta-blocker?

Angisartan belongs to the Angiotensin II Receptor Blockers (ARBs) class of medications, which works in a different way than beta-blockers. While both classes are used to treat high blood pressure, they target different systems in the body. Official drug class information defines Angisartan by its ARB classification.


Q: How long does it typically take for Angisartan to start working?

Official prescribing information indicates that a substantial blood pressure-lowering effect is typically present within one week of starting treatment. However, the maximal therapeutic effect may take longer, often requiring three to six weeks of consistent daily use.


Q: What does 'maintaining blood pressure' mean when talking about Angisartan?

When used to treat conditions like hypertension (high blood pressure), Angisartan is usually prescribed as a long-term treatment. The goal of this long-term use is consistent blood pressure management, which is associated with a reduction in long-term cardiovascular risks.


Q: What happens if I miss a dose of Angisartan?

According to official patient information, if a dose is missed, regulatory guidance is to take it as soon as it is remembered. If it is close to the time for your next scheduled dose, skip the missed dose and resume your regular schedule. It is advised not to take a double dose to make up for a missed one.


Q: Does Angisartan cause weight gain?

Clinical trials did not report weight gain as a specific side effect of Angisartan. However, official safety information does list edema (swelling caused by water retention) as an uncommon side effect, which may lead to slight weight changes for some patients.


Q: Can Angisartan affect my sleep?

The list of possible side effects documented in official labeling includes insomnia (difficulty sleeping) as a reported event. This indicates that sleep problems may occur in some patients taking the medication.


Q: What specific foods or drinks interact with Angisartan?

Official regulatory documents advise patients to avoid grapefruit and grapefruit juice because it may alter the drug's effects. Additionally, salt substitutes that contain potassium should be avoided due to the documented risk of elevating potassium levels.


Q: Can Angisartan be used to treat heart failure?

Official prescribing information indicates that Angisartan is included in the authorized uses for the treatment of heart failure in specific patient populations. The authorized uses of the drug are clearly defined in clinical guidelines.


Q: What are the main risks associated with long-term use of Angisartan?

Angisartan is often used for chronic conditions, but official labels do not classify risks strictly as 'long-term.' However, safety information highlights risks that may be managed over time, including the potential for hyperkalemia (high potassium) and changes in renal (kidney) function in susceptible patients.


Q: How long do I usually have to keep taking Angisartan?

For the treatment of chronic conditions like high blood pressure, use of Angisartan is typically long-term. Official information indicates that the medication may be required for ongoing management to maintain consistent blood pressure control.


Q: Is Angisartan meant to be a permanent treatment?

For managing chronic hypertension, treatment with Angisartan is generally regarded as long-term. Continuous use is often necessary to sustain the blood pressure reduction, which is a component of managing associated health risks.


Q: Does Angisartan make people cough?

Regulatory safety information lists cough as a common side effect reported by patients in clinical trials. It is noted that this symptom tends to occur less frequently with Angisartan compared to some other types of blood pressure medications.


Q: Is it okay to stop taking Angisartan if I feel better?

Official guidance advises that abrupt cessation of Angisartan is not recommended without consulting a healthcare professional. Stopping the medication suddenly can lead to an increase in blood pressure, which may raise the risk of serious events.


Q: How quickly do the effects of Angisartan wear off after stopping?

The parent drug, Losartan, has a terminal half-life of about 2 hours, and its active metabolite, which sustains its effect, has a half-life of approximately 6 to 9 hours. This means the substance is typically cleared from the body within a couple of days after discontinuing use.


Q: Are generic versions of Angisartan available?

Yes, the active ingredient in Angisartan, Losartan potassium, is widely available as a generic drug. This status is recognized in drug classification and availability resources.


Q: What kind of monitoring is typically required when taking Angisartan?

Due to documented safety risks, regular blood pressure checks are typically involved in monitoring. Blood tests may also be required to monitor the patient's kidney function and potassium levels, particularly for susceptible populations.


Q: Does Angisartan affect blood sugar levels?

Official safety information lists low blood sugar as a common side effect. Additionally, the drug has a specific contraindication for use with Aliskiren in patients with Type 2 diabetes, highlighting its relevance to glucose metabolism.


Q: What should I do if I think I'm experiencing an interaction with Angisartan?

If a patient experiences symptoms that suggest an interaction, especially signs of very low blood pressure or high potassium, official safety protocols recommend contacting a qualified healthcare provider without delay.


Q: What's the difference between Angisartan and a diuretic?

Angisartan is an Angiotensin II Receptor Blockers (ARB), which works by blocking a hormone receptor that constricts blood vessels. Diuretics are a different class of medicine that primarily work by increasing fluid excretion. Both are used for blood pressure management but utilize distinct biological pathways.


Q: What is the half-life of Angisartan?

Pharmacokinetic data from official documents shows that the half-life of the parent compound (Losartan) is approximately 2 hours. The active compound responsible for the sustained effect has a half-life of approximately 6 to 9 hours.


Q: Can Angisartan affect my mood?

Official safety documents have reported occurrences of depression and other mood changes in patients taking Angisartan. These effects are considered less common or serious adverse reactions.


Q: Why are there warnings about Angisartan and grapefruit juice?

Warnings exist because grapefruit juice may inhibit the enzyme CYP2C9 in the body, which is responsible for processing Angisartan. This action can potentially decrease the amount of the active metabolite in the body, which may reduce the drug's effectiveness.


Q: Does Angisartan interact with alcohol?

Yes, regulatory warnings indicate that alcohol can increase the blood pressure-lowering effect of Angisartan. This combination may increase the risk of dizziness, light-headedness, or fainting.


Q: Is a low sodium diet necessary while taking Angisartan?

While Angisartan modulates sodium excretion, official guidance notes the importance of a low-salt or low-sodium diet when following a healthcare provider's recommendations. High sodium intake can potentially reduce the expected blood pressure-lowering effect of the medication.


Q: Is Angisartan safe to take with common pain relievers like ibuprofen?

Regulatory documents caution about interactions between Angisartan and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), listing ibuprofen as an example. Concomitant use may result in a reduced blood pressure-lowering effect and potentially worsen kidney function.


Q: Does Angisartan interact with herbal supplements?

Official regulatory information advises that patients should inform their healthcare providers about all herbal products they are taking. This is recommended due to the potential for undocumented interactions or the need for careful monitoring.


How should Angisartan be stored and disposed of?

How to Store and Dispose of Angisartan (Losartan Potassium)

The official storage conditions for Angisartan tablets require the medication to be maintained at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and moisture and should be kept in its original, tightly closed container to preserve stability.

Storage and Disposal Mandates

The tablets must be stored out of the sight and reach of children.

Unused or expired Angisartan must be disposed of according to local/national regulations for pharmaceutical waste. The medication must not be disposed of in household trash or wastewater to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Angisartan found in:

A-Z Index: